-
What could Trump achieve by threatening Iran's Kharg Island?
-
India declares victory over Maoist insurgency
-
Germany's Merz pushes return of Syrians as he hosts leader Sharaa
-
G7 ministers pledge 'necessary measures' to ensure stable energy market
-
Cardiff City lose compensation case over Emiliano Sala death
-
Several French far-right mayors take down EU flags
-
Air Canada CEO to retire after row over English-only condolence message
-
Oil rises on Trump's Iran threats, stocks take cue on talks
-
Syrian leader pledges to work with Germany on migration, recovery
-
AI agent future is coming, OpenClaw creator tells AFP
-
Cardiff lose 122 mn euro compensation case over Emiliano Sala death
-
Tuchel defends Rice and Saka after England withdrawals
-
G7 ministers tackle economic fallout of Mideast war
-
Tottenham close in on De Zerbi as next boss - reports
-
Kenya's former NY marathon champion Korir gets 5-year doping ban
-
Lukaku says 'could never turn back on Napoli' after treatment row
-
Syrian leader visits Germany to talk war, recovery, refugees
-
Renault says developing ground-based military drone
-
Iran hangs two 'political prisoners' from banned opposition: activists
-
Russia expels UK diplomat on spying allegations
-
Premier League fans back call to scrap VAR
-
Italy hoping to scale World Cup 'Everest' ahead of Bosnia play-off showdown
-
Japan's cherry blossom season dazzles locals and tourists
-
EU ups mackerel quotas to match UK despite overfishing concerns
-
Crude rises, stocks drop as Houthi attacks escalate Iran war
-
Australian Rules player banned for wiping blood on face of opponent
-
Sheep culls put pressure on Greek feta cheese production
-
One man, his dog, and ChatGPT: Australia's AI vaccine saga
-
Israel PM restores access after Latin Patriarch blocked from Holy Sepulchre
-
Israel strikes Tehran as Trump says Iran deal may be reached 'soon'
-
Italy chase World Cup spot as Kosovo bid to make debut
-
Myanmar paves way for junta chief to become civilian president
-
'Long live the shah': Iranian diaspora back war at Washington rally
-
Taiwan opposition leader accepts Xi's invitation to visit China
-
French masonic lodge at heart of murky murder trial
-
US military building 'massive complex' beneath White House ballroom project: Trump
-
IPL captain takes pop at Cricket Australia over record-buy Green
-
G7 ministers set to tackle financial fallout of Mideast war
-
Premier League fans feel the pinch from ticket price hikes
-
Australia to halve fuel tax in response to Middle East war
-
Crude surges, stocks dive as Houthi attacks escalate Iran war
-
Air China resumes flights to North Korea after 6-year pause
-
NBA-best Thunder beat Knicks as Boston seal playoff spot
-
Australian fugitive shot dead by police after seven-month manhunt
-
King Kimi, Max misery, Bearman smash: Japan GP talking points
-
Philippines oil refinery secures 2.5 mn barrels of Russian crude
-
Trump says Russia can deliver oil to Cuba
-
All Blacks prop Williams out of Super Rugby season with back infection
-
Life with AI causing human brain 'fry'
-
Dubious AI detectors drive 'pay-to-humanize' scam
Ketamine pill treats depression without psychedelic effects: study
A new pill that slowly releases ketamine could treat people with severe depression without giving them the psychedelic side effects of the often-misused drug, early trial results suggested on Monday.
First developed in the 1960s as an anaesthetic, ketamine's hallucinogenic and dissociative effects led to it becoming a party drug dubbed "Special K".
However, mounting research has demonstrated that ketamine is effective for the roughly quarter of people suffering from depression who see little benefit from common anti-depressant drugs.
In many countries, ketamine has been prescribed for depression for years.
US billionaire Elon Musk told CNN in March that he regularly uses a small amount of prescribed ketamine because it is "helpful for getting one out of the negative frame of mind".
The drug has long been administered intravenously in clinics, but more recently a nasal spray using a derivative called esketamine has increased in popularity.
Both can cause patients to have side effects such as dissociation, high blood pressure and an elevated heart rate.
There are also fears that medical use of the drug could slide into abuse.
The pill described in the journal Nature Medicine on Monday takes more than 10 hours to break down in the liver, lead study author Paul Glue told AFP.
"The really interesting feedback from patients is the lack of side effects -- no euphoria, no dissociation," said the researcher at New Zealand's University of Otago.
"I don't think these tablets would appeal to people who are abusing ketamine."
- Electro-shock alternative -
The phase 2 trial involved more than 270 people with depression who had previously tried an average of four different anti-depressant drugs.
More than half taking the ketamine pill went into remission for their depression, while 70 percent of the placebo group relapsed after 13 weeks, the study said.
Julaine Allan, an expert on mental health and addiction at Australia's Charles Sturt University who was not involved in the study, praised the trial while emphasising that more research is needed.
Ketamine does not work for everyone, and the "positive effects may wear off over time," she told AFP.
Michel Hoffmann, a psychiatrist at Geneva University Hospitals, said there is "real enthusiasm" in the medical community for ketamine's potential for treating depression.
"For patients who don't respond to conventional drugs, ketamine offers a way to avoid electro-shock therapy," he told AFP.
This last-resort treatment, which involves sending electric currents through the brain, has been proven to be effective.
But it can cause memory loss -- and some patients fear the procedure after seeing depictions of it in films such as "One Flew Over the Cuckoo's Nest".
- Fears of 'opioid style crisis' -
Some psychiatrists remain hesitant to prescribe ketamine for depression, fearing their patients could end up misusing the drug.
Last year, "Friends" actor Matthew Perry became the latest high-profile death from a ketamine overdose.
US police are investigating how Perry obtained the doses that caused his death -- he had reportedly not had a supervised infusion session for several days.
One potential benefit of quick-acting ketamine seen in previous research is that it could help patients considering suicide.
But there is "the plausible concern that the widespread use of ketamine might trigger a new opioid style crisis," Oxford researcher Riccardo De Giorgi said in a 2022 BMJ editorial.
By ridding ketamine of the side effects sought by some partygoers, the slow-release pill could alleviate some of these concerns.
There were still some side effects from the pill, the most common being headaches, dizziness and anxiety.
More research including phase 3 trials is needed before the drug can be reviewed by national medicine agencies, meaning it will be at least two or three years before patients could potentially access the pills, Glue said.
H.Thompson--AT